Chronic Inflammatory Demyelinating Polyneuropathy

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a neurological disorder characterized by progressive weakness and impaired sensory function in the arms and legs.

Featured Video

European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second Revision

CIDP

Watch Dr. Peter Van den Bergh, lead author, take you through the highlights of the guideline.

Videos about CIDP

VIEW ALL VIDEOS

Restabilization of chronic inflammatory demyelinating polyneuropathy patients with IVIG: restabilization phase of the PATH study

Vera Bril, BSc, FRCPC, MD

University of Toronto,Toronto, Canada

12:13 MIN

CIDP

Learn about the Restabilization Phase of the PATH Trial with IVIG in CIDP patients

DOWNLOAD PDF

Subcutaneous Immunoglobulins (SCIg) in Responders to Intravenous Immunoglobulins (IVIg) with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)

Nabil Moumane, MD

Medical Affairs and Pharmacology, CSL Behring

3:00 MIN

CIDP
MMN

Hear why SCIg may be a better option for long-term treatment of patients on Immunoglobulin therapy with difficult venous access.

DOWNLOAD PDF

Improving CIDP Diagnosis: The Challenges of Under and Over Diagnosis

Jeffrey A. Allen, MD

University of Minnesota

12:30 MIN

CIDP

Understand the challenges associated with accurately diagnosing CIDP

DOWNLOAD PDF

The GRIPPER study: Quantifying IVIG Treatment-Related Fluctuations in CIDP Using Daily Grip Strength Measurements

Jeffrey A. Allen, MD

University of Minnesota

12:15 MIN

CIDP

Learn more about grip strength as an outcome measure in CIDP and how it is utilized in the Gripper Study as a daily measure of treatment-related fluctuations in IVIg-treated patients.

DOWNLOAD PDF

NOW PLAYING

12:13

Restabilization of chronic inflammatory demyelinating polyneuropathy patients with IVIG: restabiliza...

Learn about the Restabilization Phase of the PATH Trial with IVIG in CIDP patients

NOW PLAYING

3:00

Subcutaneous Immunoglobulins (SCIg) in Responders to Intravenous Immunoglobulins (IVIg) with Chronic...

Hear why SCIg may be a better option for long-term treatment of patients on Immunoglobulin therapy with difficult venous access.

NOW PLAYING

12:30

Improving CIDP Diagnosis: The Challenges of Under and Over Diagnosis

Understand the challenges associated with accurately diagnosing CIDP

NOW PLAYING

12:15

The GRIPPER study: Quantifying IVIG Treatment-Related Fluctuations in CIDP Using Daily Grip Strength...

Learn more about grip strength as an outcome measure in CIDP and how it is utilized in the Gripper Study as a daily measure of treatment-related fluctuations in IVIg-treated patients.

Our Experts on CIDP

VIEW ALL EXPERTS

Vera Bril, BSc, FRCPC, MD

University of Toronto,Toronto, Canada

Vera Bril, BSc, FRCPC, MD

University of Toronto,Toronto, Canada

CIDP

Vera Bril is a Professor of Medicine (Neurology) at the University of Toronto, Director of Neurology at University Health Network and Mount Sinai Hospital and the Krembil Family Chair in Neurology.

Thomas Harbo, MD, PhD

Aarhus University Hospital in Aarhus, Denmark

Thomas Harbo, MD, PhD

Aarhus University Hospital in Aarhus, Denmark

CIDP
GBS

Dr. Harbo is a neuromuscular specialist at Aarhus University Hospital in Aarhus, Denmark, a certified Centre of Excellence by the GBS|CIDP Foundation International.

Carol L. Koski, MD

GBS/CIDP Foundation International

Carol L. Koski, MD

GBS/CIDP Foundation International

CIDP
GBS

Dr. Koski is a retired Professor of Neurology from the University of Maryland School of Medicine and is currently a Director of the GBS/CIDP Foundation International.

Karissa Gable, MD

Duke University Medical Center in Durham, North Carolina